Advanced Search

 

Study ID Status Title Patient Level Data
S2BS77 Completed A double-blind, placebo-controlled, parallel group study of 6mg + optional 6 mg subcutaneous GR43175C (sumatriptan) administered using the Glaxo autoinjector during the aura phase of a migraine attack with an optional open six month extension.
S2BS78 Completed A double-blind, placebo-controlled, parallel group study of 6mg subcutaneous sumatriptan + optional 6mg subcutaneous sumatriptan administered using a novel cartridge system self-injector in slow developing migraine.
S2BT16 Completed A double-blind, placebo-controlled, crossover study to evaluate oral GR43175C 100 mg in the acute treatment of migraine.
S2BT27 Completed A double-blind study to compare oral GR43175C (100mg) with oral aspirin (900mg) plus metoclopramide (10mg) in the acute treatment of migraine over a six month period.
S2BT33 Completed An open design study to evaluate repeat-dose oral sumatriptan (100 mg plus optional 100 mg plus optional further 100 mg for recurrent headache) in the acute treatment of migraine attacks during a 24-month period.
S2BT57 Completed An open design study to evaluate the safety of rectal dosing with sumatriptan (25mg and optional 25mg dose for headache recurrence) in the acute treatment of all migraine attacks over a 12 month period.
S2CP46 Completed An in-clinic pilot study to examine the efficacy and safety of oral GR43175C (50mg or 100mg) for the acute treatment of migraine in adolescents.
S2CP81 Completed The acute treatment of episodic tension-type headache with oral GR43175C (100mg) – a double-blind, placebo-controlled, parallel group pilot study.
S2CT34 Completed A double-blind study to compare the efficacy of a repeat dose of oral GR43175C regimen (plus a further optional dose for recurrence) with placebo in the acute treatment of migraine.
S2CT37 Completed A double-blind study to compare the efficacy and safety or oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents.
S2CT40 Completed A double-blind study to compare the efficacy and safety of oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents.
S2CT41 Completed Pre-emptive oral GR43175C treatment during a cluster headache period – (100mg tid for 7 days) – A double-blind, parallel group, placebo controlled study.
S2W20006 Completed A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria. Study Listed on ClinicalStudyDataRequest.com
S2W30018 Completed An open study of the efficacy and tolerability of naratriptan in prophylactic treatment of pure menstrual migraine attacks.
S2W40010 Completed A randomised, double-blind, cross-over study to compare the patient preference of oral Naratriptan (Naramig) 2.5mg with Naproxen 500mg in patients dissatisfied with simple analgesics in the treatment of acute migraine.
S2W40012 Completed A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily asprophylactic treatment for menstrually-associated migraine.
S2W40016 Completed Efficacy and tolerability of oral sumatriptan 50mg, as acute treatment for mild to moderate migraine, in patients not responders to common analgesics or anti-inflammatories.
S2W40024 Completed A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine. Study Listed on ClinicalStudyDataRequest.com
S2W40027 Completed An open-label evaluation of the long-term safety of oral naratriptan 1mg twice daily as short-term prophylactic treatment for menstrually-associated migraine. Study Listed on ClinicalStudyDataRequest.com
S2W40028 Completed A multicentre, open label trial to evaluate patient preference for Amerge® 2.5 mg in the acute treatment of migraine.
S2W40031 Completed A double-blind, randomised, parallel-group design, placebo-controlled study of the effects of naratriptan tablets 2.5mg in treatment of menstrually-associated migraine attack at a stage of mild pain.
S2WA1002 Completed A study to evaluate the pharmacokinetics of two doses of 1.0mg, 2.5mg and 5.0mg GR85548A tablets separated by 2 hours in healthy volunteers.
S2WA1003 Completed A study to determine the effect of food on the pharmacokinetics of oral naratriptan tablets in healthy female volunteers.
S2WA1004 Completed A comparative study of the pharmacologic effects of naratriptan, codeine and placebo in experienced psychoactive substance users.
S2WA1007 Completed A study to evaluate the pharmacokinetics and pharmacodynamics of oral naratriptan in migraine subjects.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.